Aims/hypothesis. Patients with diabetes are characterised by endothelial dysfunction and cardiovascular mortality. In particular endothelium-derived nitric oxide has emerged as a first line mechanism against atherosclerosis. Hyperglycaemia causes oxygen radical stress but has also been associated with endothelial nitric oxide synthase uncoupling, both lead to decreased nitric oxide-availability. We recently showed that folate reverses eNOS uncoupling in vitro. Therefore we hypothesise that folate improves endothelial function in Type II (non-insulin-dependent) diabetes mellitus in vivo. Methods. Using forearm plethysmography, we evaluated the effect of local, intra-arterial administration of 5-methyltetrahydrofolate (5-MTHF, the active form of folic acid, 1 µg/100 ml FAV/min) on forearm blood flow in 23 patients with Type II diabetes and 21 control subjects, matched for age, sex, blood pressure, body mass index, weight and smoking habits. Serotonin as a stimulator of nitric oxide-dependent vasodilation and sodium nitroprusside as a stimulator of endothelium-independent vasodilation were infused. Results. Serotonin-induced vasodilation was blunted (53±30 vs 102±66 M/C%, p<0.005) and nitroprussideinduced vasodilation was mildly reduced (275±146 vs 391±203 M/C%, p<0.05) in patients with Type II diabetes compared to control subjects. 5-MTHF improved nitric oxide-mediated vasodilation (from 53±30 to 88±59 M/C%, p<0.05) in patients with Type II diabetes mellitus. As expected, 5-MTHF had no effect on forearm blood flow in control subjects. Conclusion/interpretation. These data imply that folate can be used to improve nitric oxide status and to restore endothelial dysfunction in patients with Type II diabetes. Our results provide a strong rationale for the initiation of studies that investigate whether supplementation with folic acid prevents future cardiovascular events in this patient group. [Diabetologia (2002[Diabetologia ( ) 45:1004[Diabetologia ( -1010 
resulting in high morbidity and mortality. Aggressive management of cardiovascular risk factors such as hypertension and dyslipidaemia has been shown to prevent cardiovascular and other long-term complications in diabetic patients [1, 2, 3] . Nevertheless, diabetes-related cardiovascular mortality is increasing while risk factor management in diabetic patients is notoriously difficult [4] .
It is clear that additional strategies that reduce atherosclerosis and vascular injury in diabetic patients will be of great clinical importance. Particularly if these strategies are safe and easily applicable.
Type II (non-insulin-dependent) diabetes mellitus is characterised by early development of atherosclerosis
The endothelium, and in particular endotheliumderived nitric oxide (NO) has emerged as a first line defence mechanism against atherosclerosis. It has been shown that impaired NO-dependent vasodilation predicts the outcome in cardiovascular compromised patient groups [5, 6, 7] . In diabetes, impaired NO availability has been shown [8, 9, 10, 11, 12] and could be related to the common risk factors, such as hypertension and dyslipidemia. Hyperglycaemia itself could have direct effects on NO availability. High glucose has been shown to increase oxygen radical formation in endothelial cells [13] which causes enhanced NO degradation. The NO-producing enzyme, endothelial NO-synthase (eNOS), 'uncouples' under hyperglycaemic conditions; i.e. eNOS produces superoxide rather than NO [13] . Oxidative modification of the NOS co-factor tetrahydrobiopterin (BH 4 ) is probably the key in this phenomenon [14] . Indeed, in vivo, BH 4 supplementation has been shown to restore eNOS function and reduce vascular oxidative stress in insulin-resistant rats [15] .
Of interest, amelioration of eNOS function also can be achieved by using folic acid. The active form of folic acid, 5-methyltetrahydrofolate (5-MTHF), restores the function of uncoupled eNOS. Although the exact mechanism by which 5-MTHF acts is not known, it is clear that its effects are BH 4 -dependent [16] . Endothelial cells produce twofold more NO in the presence of folate [16] .
Both intra-arterial administration of 5-MTHF as well as oral supplementation of folic acid restore endothelial function in patients with familial hypercholesterolaemia [17, 18] . The beneficial effects encountered in hypercholesterolaemic patients do not necessarily predict similar effects in diabetic patients. In our study we investigated whether folate could also restore NO availability in vivo in Type II diabetic patients. If folate is capable of restoring the endothelial dysfunction, commonly encountered in diabetic patients, this could have important clinical implications because endothelial dysfunction is associated with increased cardiovascular risk.
Subjects and methods

Subjects.
We recruited 25 patients with Type II diabetes mellitus and 21 control subjects, matched for age, sex, BMI, weight, smoking habits and blood pressure. Two patients with Type II diabetes were withdrawn from the study before the start of the vascular assessments (one because of technical difficulties due to cannulation of the brachial artery and one patient was lost during follow-up). A total of 23 patients with Type II diabetes and 21 control subjects completed the study. The median duration of diabetes was 8 years (range 1-to-24 years). Diabetes was treated by insulin in eleven patients, by oral hypoglycaemic drugs in eight patients and by both insulin and oral hypoglycaemic drugs in four patients. None of the patients or control subjects had evidence of clinical macrovascular disease or macroalbuminuria. Only four patients with diabetes had microalbuminuria, assessed by a qualitative method (ComburTest, Roche, Mannheim, Germany). Studies were carried out at least 4 weeks after withdrawal of confounding vasoactive medication such as lipid lowering medication, angiotensin converting enzyme inhibitors, angiotensin receptor blockers, nitrates, calcium channel blockers, estrogens, non-steroidal anti inflammatory drugs (NSAID's) and vitamin supplementation. Insulin-treated patients did not receive insulin on the morning of and during the vascular assessments.
This study was designed as an open-label study. Subjects served as their own control. The study was not placebo controlled.
All subjects gave written informed consent and the local research ethics committee of the University Medical Center Utrecht approved the protocol. All studies were carried out in accordance with local institutional guidelines in our GCPcertified unit.
Forearm plethysmography. All subjects refrained from alcohol, tobacco and drinks containing caffeine and fasted for at least 12 hours before the measurements were done. Measurements were done in a quiet room with a constant normal temperature (22-24°C) . Forearm blood flow (FBF) was measured in both arms by venous occlusion mercury strain gauge plethysmography (Hokanson EC-4, Bellevue, Wash., USA) [17, 18, 19, 20, 21] . In previous experiments from our group with patients with Type II diabetes the variance was 0.45, using the same plethysmography system. A microcomputer based, R-wave triggered system for online monitoring was used. Upper-arm cuffs were inflated automatically to 40 mmHg during four heartbeats, four times a minute during the last 3 min of every measurement. Wrist cuffs were inflated to 200 mmHg or at least 40 mmHg above systolic blood pressure to exclude the hands from the circulation [22] . FBF measurements were recorded during the last 2 to 3 min of every 5 to 7-min period of infusion of saline or drug, at 5 min intervals. The brachial artery of the nondominant arm was cannulated with a 20-gauge flexible, polyurethane catheter (Arrow International, USA). Saline 0.9% (Baxter Healthcare, Deerfield, Ill., USA) was infused for at least 45 min before intra arterial administration of vasoactive drugs. All drugs were administered at a constant infusion rate of 90 ml/h. Serotonin (5-HT, Sigma Chemicals, St. Louis, Mo., USA) was infused into the brachial artery at increasing doses of 0, 0.6, 1.8, 6.0 ng/100 ml forearm volume (FAV)/min. This protocol has previously been shown to cause a dose-dependent increase in endothelium-dependent, NO-mediated vasodilation. We and others have shown that the effect of serotonin can be completely abolished by L-NMMA, a specific inhibitor of NO [19, 20, 21, 23] . Acetylcholine, which also can be used to investigate endothelium-dependent vasodilation is less specific as it stimulates both NO and EDHF. Sodium nitroprusside (SNP, Merck, Germany) was infused at increasing doses of 0, 6, 60, 180 and 600 ng/100 ml FAV/min to assess endotheliumindependent vasodilation. The order of the infusions was randomised. Measurements with serotonin and sodium nitroprusside were repeated during and after at least 30 min intra-arterial co-infusion of 5-methyltetrahydrofolate (5 MTHF, AHP Pharma, the Netherlands) at an infusion rate of 1 µg/100 ml FAV/min. This protocol has been shown to increase local folate values in the venous effluent of the infused arm from 9.4 to 307 nmol/l in control subjects and from 9.1 to 240 nmol/l in patients with familial hypercholesterolaemia. For comparison, oral supplementation of folic acid (5 mg od) increases folate levels to around 150 nmol/l [17, 18] . All infusates were prepared in a pharmacy department in accordance with GMP guidelines.
Statistical analysis. The forearm blood flow (FBF) recordings made in the first 30 s after wrist cuff inflation were not used for analysis. Average values of the FBF of the measurement (cannulated) and control arm were obtained from the last four to six recordings of each measurement period. The ratio of flow in the infused measurement (M) and non-infused control (C) arm was calculated for each recording (M:C ratio). The average value of the M:C ratio was calculated from these four to six M:C ratios. This M:C ratio provides an internal control by excluding systemic factors from influencing the results [24] . Forearm blood flow data for each vasoactive agent are shown in the text as the mean response (±SD) at baseline and during infusion of the highest dose. The results are expressed as M:C ratio or percentage change of M:C ratio from baseline M:C ratio (M:C%). Differences in forearm reactivity were analysed with paired and unpaired Student's t tests. In case of non-normal distribution the Wilcoxon Signed Rank test or the Mann Whitney U test was used. Group comparisons with respect to unmatched clinical characteristics were made with unpaired and two-tailed Student's t tests. The study was designed to detect an increase of the M:C-ratio of 0.4 of the highest dose of serotonin after folate co-infusion. We needed 20 subjects to show this difference with an alpha of 0.05 (two-sided) and 80% power based on a standard deviation of 0.6 (M:C ratio) from our previous studies. Statistical significance was taken at the 5% level.
Results
Subjects. Clinical characteristics of the subjects are shown in Table 1 . As expected, serum concentration of fasting plasma glucose (FPG) (p<0.0001), glycosylated haemoglobin (HbA 1c ) (p<0.0001), total cholesterol (p<0.05), LDL (p<0.05) and triglycerides (p<0.01) were higher in diabetic patients. HDL (p<0.01) was lower in diabetic patients.
Baseline forearm blood flow per se tends to be higher in patients with Type II diabetes compared to the control group but this difference is not significant (3.4±1.2 vs 2.7±0.9 ml/100 ml FAV/min, respectively, NS). Baseline forearm blood flow expressed as M:C ratio was similar in both groups (1.2±0.3 vs 1.3±0.5, respectively). (Fig. 1) . In patients with Type II diabetes, 5-MTHF had no effect on nitroprusside-induced vasodilation [M:C ratio from 1.2±0.4 to 4.3±2.1 (increase 275± 146 M:C%) without 5-MTHF co-infusion vs M:C ratio from 1.4±0.5 to 4.3±1.6 (increase 235±121 M:C %) with 5-MTHF co-infusion, NS] (Fig. 2) .
Serotonin-induced and sodium nitroprusside-induced vasodilation in patients with
Effect of 5-MTHF co-infusion on serotonin-induced
and sodium nitroprusside-induced vasodilation in the control subjects. 5-MTHF had no effect on baseline M:C ratio in control subjects (1.3±0.5 vs 1.3±0. infusion. These data indicate an important role of 5-MTHF on endogenous NO-availability and could support previous studies suggesting a direct beneficial effect of 5-MTHF on NO-synthase function. This effect occurred despite the presence of mild dyslipidaemia, hypertension and increased glucose concentrations. These factors are all known to affect NO availability. In the context of the increasing evidence that endothelial dysfunction predicts cardiovascular events this finding is relevant for the treatment of patients with diabetes.
Vascular responses at baseline. Baseline forearm blood flow per se was slightly higher in patients with Type II diabetes compared to the control group. This could be due to the osmotic effect of glucose as this phenomenon in the forearm is also seen during hyperglycaemia due to infusion of glucose and during equimolar infusion of mannitol [25, 26] . Baseline forearm blood flow expressed as M:C ratio was similar in both groups.
Most studies evaluating vascular reactivity in patients with Type II diabetes have observed impaired endothelium-dependent responses in forearm blood vessels [8, 9, 10, 11] . We show an impaired serotonin-induced vasodilation in forearm resistance arteries in patients with Type II diabetes. Serotonin responses can be completely blocked by NO-inhibition [19, 20, 21, 23 ] strongly suggesting a specific defect in endothelial NO release in these diabetic patients.
Type II diabetic patients are almost inevitably characterised by the presence of concomitant cardiovascular risk factors such as hypertension, dyslipidaemia and overweight, which can negatively affect vascular responses. The diabetic patients studied are representative for the general Type II diabetic population. The simultaneous assessment of a control group, matched for age, sex, weight, smoking habits and blood pressure allows exclusion of these matched conventional risk factors as major cause for the difference between diabetic patients and control subjects in this study. As expected, a difference could be shown between total-, LDL-and HDL-cholesterol and triglycerides from diabetic patients and control subjects. The degree of diabetes-related dyslipidaemia was mild with a disproportionally severe impairment in NO-mediated dilatation. In comparison, in studies from our laboratory in severely dyslipidaemic patients with familial hyperlipidaemias, the disturbance in NO-mediated vasodilation was milder than the disturbance in the currently studied diabetic group [17, 18, 19] . This implies that specific diabetes-related factors are largely responsible for the impaired NO-dependent responses in these patients.
In the study group of Type II diabetic patients we also observed a mild impairment of the endotheliumindependent response. This has also been shown by 5-MTHF co-infusion versus M:C ratio from 1.3±0.4 to 5.3±2.0 (increase 333±219 M:C %) with 5-MTHF co-infusion, NS].
Discussion
The main feature of this study is that, in patients with Type II diabetes, administration of 5-MTHF, the active form of folic acid, restores endothelial dysfunction as measured by serotonin-induced vasodilation. In addition to serotonin-induced vasodilation, also nitroprusside-induced vasodilation was impaired in patients with Type II diabetes. Nitroprusside-induced vasodilation, however, was not affected by 5-MTHF Fig. 2 . Change in M:C ratio after stimulation of endotheliumindependent vasodilation by sodium nitroprusside. Endotheliumindependent vasodilation is modestly reduced in patients with Type II diabetes (s s) compared with matched control subjects (q). (#p<0.05). 5-MTHF has no effect on endothelium-independent vasodilation in patients with Type II diabetes (s) Fig. 1 . Change in M:C ratio after stimulation of NO-mediated, endothelium-dependent vasodilation with serotonin. NO-dependent vasodilation is impaired in patients with Type II diabetes (s s) compared with matched control subjects (q q) (*p<0.01, **p<0.005). 5-MTHF normalised NO-mediated vasodilation in patients with Type II diabetes (s) (#p<0.05) others [9, 10] . However, whereas decreased responsiveness of the smooth muscle cells to NO and/or enhanced generation of endothelium-derived constricting factors [27, 28] might have contributed to the impaired endothelium-dependent NO-mediated vasodilator response, this data suggests a vital defect in endothelium-derived NO bioavailability in patients with Type II diabetes.
Effect of 5-MTHF administration on forearm vasomotion. We showed that 5-MTHF administration restores impaired NO-mediated vasodilation in patients with Type II diabetes despite the presence of several diabetes-related risk factors such as hyperglycaemia, dyslipidaemia and hypertension. Impaired NO availability in diabetes could be the result of increased degradation of NO by oxygen radicals or the result of decreased formation of NO. With regard to increased breakdown of NO, several mechanisms have been suggested to contribute to increased oxygen radical formation in diabetes [29] . Advanced glycation end products could induce radical formation directly as well as indirectly by activating their cellular receptors (RAGE) [30, 31, 32] . In addition, hyperglycaemia leads to activation of protein kinase C [33, 34] , which has also been shown to result in the induction of oxygen radical stress [35] . Activation of the polyol pathway by hyperglycaemia and glucoseauto oxidation are able to induce oxygen radical stress [36, 37] . Increased formation of superoxide (O2-) and the subsequent reaction with NO results in the formation of the highly cytotoxic peroxynitrite (ONOO-) [38] .
Oxidative stress has been shown to induce oxidation of BH 4 [14] and subsequently contributes to eNOS uncoupling, i.e. reduced NO production and increased eNOS-derived superoxide production [39, 40, 41] . Indeed BH 4 supplementation has been shown to improve endothelial function in in vivo conditions characterised by increased oxidative stress such as human hypercholesterolaemia [42] , coronary artery disease [43] and experimental diabetes [44] .
Recently, we were able to show that, on a molecular level, administration of 5-MTHF, the active form of the pterin folic acid, restores the function of 'uncoupled' eNOS in a BH 4 -dependent manner [16] . The exact mechanism is not known. 5-MTHF is a 20-fold less effective anti-oxidant compared to the well known anti-oxidant vitamin C. It has been suggested that folate acts as a facilitator of the effect of BH 4 on electron flux of NOS [16] . Our study is in line with this pathophysiological concept as we observe an effect of 5-MTHF administration on endothelium-dependent, NO-mediated vasodilation in Type II diabetes. The ameliorative effect of 5-MTHF seems to be specific for endothelium-derived NO, because an improvement could not be observed for endothelium-independent NO-mediated vasodilation.
Several studies have shown that folic acid treatment reduces homocysteine concentrations [45, 46] . Patients with hyperhomocysteinaemia have endothelial dysfunction which can be improved by folic acid [47, 48] . We have previously shown in patients with familial hypercholesterolemia that acute administration of 5-MTHF in the forearm vasculature increased folic acid concentrations and improves endothelial function without affecting homocysteine concentrations [18] . Although we cannot exclude the possibility of an effect of folate on homocysteine concentrations based upon these earlier results this effect is not likely in our study.
We show a specific ameliorative effect of the active form of folic acid, 5-MTHF, on endothelial dysfunction as measured by endothelium-dependent NO-mediated vasodilation in patients with uncomplicated Type II diabetes. This could be of clinical importance since endothelial dysfunction is associated with increased cardiovascular risk. Our results provide a strong rationale for the initiation of studies that investigate whether in this patient group supplementation with folic acid, a safe, readily available, not expensive and well-tolerated drug, prevents future cardiovascular events. Impaired nitric oxide production in coronary endothelial cells of the spontaneously diabetic rat is due to tetrahydrobiopterin deficiency. 
